We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · June 28, 2022

Fulvestrant Plus Capivasertib vs Placebo After Relapse or Progression on an Aromatase Inhibitor in Patients With ER+, HER2− MBC

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
Lancet Oncol 2022 Jun 01;[EPub Ahead of Print], SJ Howell, A Casbard, M Carucci, K Ingarfield, R Butler, S Morgan, M Meissner, C Bale, P Bezecny, S Moon, C Twelves, R Venkitaraman, S Waters, EC de Bruin, G Schiavon, A Foxley, RH Jones

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading